2.4. Intragroup Comparisons between Potassium Canrenoate and Placebo Groups on Day 1 versus Day 7
Intragroup comparisons using Wilcoxon’s test were performed to specify if the assessment of the dynamics of change between potassium canrenoate and placebo group or intragroup showed significant differences between day 1 and day 7. The results are shown in The CD3% for potassium canrenoate increased significantly between day 1 and day 7 (12.85 ± 9.46; 11.55 vs. 20.50 ± 14.40; 17.80; The interleukin-1ß total count (%) increased significantly over time for both potassium canrenoate (0.68 ± 0.58; 0.45 vs. 1.27 ± 0.83; 1.20; TNF-α total count (%) decreased significantly for potassium canrenoate between day 1 and day 7 (0.54 ± 0.45; 0.40 vs. 0.25 ± 0.23; 0.10; Interleukin-6 (pg/mL) showed a significant decrease between day 1 and day 7 for potassium canrenoate (64.97 ± 72.52; 41.00 vs. 24.20 ± 69.38; 5.30; 